Secreted proteins encoded by human chromosome 13
AssigneeZymoGenetics, Inc.
InventorsPaul O. Sheppard, Debra G. Gilbertson
Life of this patent
Estimating the term…
Abstract
The present invention relates to polynucleotide and polypeptide molecules a for zsig46 polypeptide, a novel secreted protein located on human chromosome 13. The zsig46 polypeptides, and polynucleotides encoding them, are secreted proteins and may be used in the study of receptors for which a ligand has not yet been identified, of secretory pathways and the like. The present invention also includes antibodies to the zsig46 polypeptides.
Claims33
An isolated polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 31-346 of SEQ ID NO:2, wherein said sequence comprises cysteine residues corresponding to residues 58, 65, 132, 147, 153 and 219 of SEQ ID NO:2.
An isolated polypeptide having a sequence of amino acid residues selected from the group consisting of:
- a) a sequence of amino acid residues from amino acid residue 1 to amino acid residue 37 of SEQ ID NO:
- 2;
- b) a sequence of amino acid residues from amino acid residue 29 to amino acid residue 37 of SEQ ID NO:
- 2;
- c) a sequence of amino acid residues from amino acid residue 31 to amino acid residue 37 of SEQ ID NO:
- 2;
- d) a sequence of amino acid residues from amino acid residue 29 to amino acid residue 45 of SEQ ID NO:
- 2;
- e) a sequence of amino acid residues from amino acid residue 31 to amino acid residue 45 of SEQ ID NO:
- 2;
- f) a sequence of amino acid residues from amino acid residue 40 to amino acid residue 45 of SEQ ID NO:
- 2;
- g) a sequence of amino acid residues from amino acid residue 40 to amino acid residue 346 of SEQ ID NO:
- 2;
- h) a sequence of amino acid residues from amino acid residue 48 to amino acid residue 346 of SEQ ID NO:
- 2;
- i) a sequence of amino acid residues from amino acid residues 29 to amino acid residue 276 of SEQ ID NO:2;
- j) a sequence of amino acid residues from amino acid residues 31 to amino acid residue 276 of SEQ ID NO:2;
- k) a sequence of amino acid residues from amino acid residues 40 to amino acid residue 276 of SEQ ID NO:2;
- l) a sequence of amino acid residues from amino acid residues 48 to amino acid residue 276 of SEQ ID NO:2;
- m) a sequence of amino acid residues from amino acid residue 278 to amino acid residue 346 of SEQ ID NO:
- 2;
- and
- n) a sequence of amino acid residues that is at least 80% identical in amino acid sequence to a), b), c), d), e), f), g), h), i), j), k), l) or m).
A fusion protein consisting essentially of a first portion and a second portion joined by a peptide bond, said first portion comprising a polypeptide that is at least 80% identical in amino acid sequence to the amino acid sequence of a polypeptide selected from the group consisting of:
- a) a sequence of amino acid residues from amino acid residue 1 to amino acid residue 37 of SEQ ID NO:
- 2;
- b) a sequence of amino acid residues from amino acid residue 29 to amino acid residue 37 of SEQ ID NO:
- 2;
- c) a sequence of amino acid residues from amino acid residue 31 to amino acid residue 37 of SEQ ID NO:
- 2;
- d) a sequence of amino acid residues from amino acid residue 29 to amino acid residue 45 of SEQ ID NO:
- 2;
- e) a sequence of amino acid residues from amino acid residue 31 to amino acid residue 45 of SEQ ID NO:
- 2;
- f) a sequence of amino acid residues from amino acid residue 40 to amino acid residue 45 of SEQ ID NO:
- 2;
- g) a sequence of amino acid residues from amino acid residue 40 to amino acid residue 346 of SEQ ID NO:
- 2;
- h) a sequence of amino acid residues from amino acid residue 48 to amino acid residue 346 of SEQ ID NO:
- 2;
- i) a sequence of amino acid residues from amino acid residues 29 to amino acid residue 276 of SEQ ID NO:2;
- j) a sequence of amino acid residues from amino acid residues 31 to amino acid residue 276 of SEQ ID NO:2;
- k) a sequence of amino acid residues from amino acid residues 40 to amino acid residue 276 of SEQ ID NO:2;
- l) a sequence of amino acid residues from amino acid residues 48 to amino acid residue 276 of SEQ ID NO:2;
- m) a sequence of amino acid residues from amino acid residue 278 to amino acid residue 346 of SEQ ID NO:
- 2;
- o) a sequence of amino acid residues from amino acid residue 1 to amino acid residue 346 of SEQ ID NO:
- 2;
- p) a sequence of amino acid residues from amino acid residue 29 to amino acid residue 346 of SEQ ID NO:
- 2;
- and
- q) a sequence of amino acid residues from amino acid residue 31 to amino acid residue 346 of SEQ ID NO:
- 2;
- and
- said second portion comprising another polypeptide.
A fusion protein comprising a secretory signal sequence having the amino acid sequence of amino acid residues 1-28 or 1-30 of SEQ ID NO:2, wherein said secretory signal sequence is operably linked to an additional polypeptide.
An isolated protein comprising a first polypeptide that is at least 80% identical in amino acid sequence to the amino acid sequence of a polypeptide selected from the group consisting of:
- a) amino acid residues 1-29 of SEQ ID NO:2, said polypeptide comprising a cysteine residue at a position corresponding to residue 15 of SEQ ID NO:2;
- b) amino acid residues 1-30 of SEQ ID NO:2, said polypeptide comprising a cysteine residue at a position corresponding to residue 15 of SEQ ID NO:2;
- c) amino acid residues 48-276 of SEQ ID NO:2, said polypeptide comprising cysteine residues at positions corresponding to residues 58, 65, 132, 147, 153 and 219 of SEQ ID NO:2;
- and
- d) amino acid residues 31-346 of SEQ ID NO:2, said polypeptide comprising cysteine residues at positions corresponding to residues 58, 65, 132, 147, 153 and 219 of SEQ ID NO:2;
- complexed to a second polypeptide.
An expression vector comprising the following operably linked elements:
- a transcription promoter;
- a DNA segment encoding a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 31-346 of SEQ ID NO:2, wherein said sequence comprises cysteine residues corresponding to residues 58, 65, 132, 147, 153 and 219 of SEQ ID NO:2;
- and
- a transcription terminator.
A cultured cell into which has been introduced an expression vector comprising the following operably linked elements:
- a transcription promoter;
- a DNA segment encoding a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 31-346 of SEQ ID NO:2, wherein said sequence comprises cysteine residues corresponding to residues 58, 65, 132, 147, 153 and 219 of SEQ ID NO:2;
- and
- a transcription terminator, wherein said cell expresses said polypeptide encoded by said DNA segment.
A method of producing a polypeptide comprising:
- culturing a cell into which has been introduced an expression vector comprising the following operably linked elements:
- a transcription promoter;
- a DNA segment encoding a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 31-346 of SEQ ID NO:2, wherein said sequence comprises cysteine residues corresponding to residues 58, 65, 132, 147, 153 and 219 of SEQ ID NO:2;
- and
- a transcription terminator;
- whereby said cell expresses said polypeptide encoded by said DNA segment;
- and
- recovering said expressed polypeptide.
A pharmaceutical composition comprising a polypeptide, said polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 31-346 of SEQ ID NO:2, wherein said sequence comprises cysteine residues corresponding to residues 58, 65, 132, 147, 153 and 219 of SEQ ID NO:2;
- in combination with a pharmaceutically acceptable vehicle.
An antibody that specifically binds to an epitope of a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 31-346 of SEQ ID NO:2, wherein said sequence comprises cysteine residues corresponding to residues 58, 65, 132, 147, 153 and 219 of SEQ ID NO:2.
A binding protein that specifically binds to an epitope of a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 31-346 of SEQ ID NO:2, wherein said sequence comprises cysteine residues corresponding to residues 58, 65, 132, 147, 153 and 219 of SEQ ID NO:2.
An isolated polynucleotide encoding a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 31-346 of SEQ ID NO:2, wherein said sequence comprises cysteine residues corresponding to residues 58, 65, 132, 147, 153 and 219 of SEQ ID NO:2.
An isolated polynucleotide selected from the group consisting of:
- a) a sequence of nucleotides from nucleotide 47 to nucleotide 157 of SEQ ID NO:1;
- b) a sequence of nucleotides from nucleotide 131 to nucleotide 157 of SEQ ID NO:1;
- c) a sequence of nucleotides from nucleotide 137 to nucleotide 157 of SEQ ID NO:1;
- d) a sequence of nucleotides from nucleotide 131 to nucleotide 181 of SEQ ID NO:1;
- e) a sequence of nucleotides from nucleotide 137 to nucleotide 181 of SEQ ID NO:1;
- f) a sequence of nucleotides from nucleotide 164 to nucleotide 1084 of SEQ ID NO:1;
- g) a sequence of nucleotides from nucleotide 188 to nucleotide 1084 of SEQ ID NO:1;
- h) a sequence of nucleotides from nucleotide 164 to nucleotide 181 of SEQ ID NO:1;
- i) nucleotide sequences complementary to a), b), c), d), e), f), g) or h);
- and
- j) degenerate nucleotide sequences of a), b), c), d), e), f), g), h) or i).
An isolated polynucleotide selected from the group consisting of:
- a) a sequence of nucleotides from nucleotide 131 to nucleotide 874 of SEQ ID NO:1;
- b) a sequence of nucleotides from nucleotide 137 to nucleotide 874 of SEQ ID NO:1;
- c) a sequence of nucleotides from nucleotide 164 to nucleotide 874 of SEQ ID NO:1;
- d) a sequence of nucleotides from nucleotide 188 to nucleotide 874 of SEQ ID NO:1;
- e) a sequence of nucleotides from nucleotide 878 to nucleotide 1084 of SEQ ID NO:1;
- f) nucleotide sequences complementary to a), b), c), d) or e) and
- g) degenerate nucleotide sequences of a), b), c), d), e) or f).
An isolated polynucleotide encoding a fusion protein consisting essentially of a first portion and a second portion joined by a peptide bond, said first portion is a polypeptide that is at least 80% identical in amino acid sequence to the amino acid sequence of a polypeptide selected from the group consisting of:
- a) a sequence of amino acid residues from amino acid residue 1 to amino acid residue 37 of SEQ ID NO:
- 2;
- b) a sequence of amino acid residues from amino acid residue 29 to amino acid residue 37 of SEQ ID NO:
- 2;
- c) a sequence of amino acid residues from amino acid residue 31 to amino acid residue 37 of SEQ ID NO:
- 2;
- d) a sequence of amino acid residues from amino acid residue 29 to amino acid residue 45 of SEQ ID NO:
- 2;
- e) a sequence of amino acid residues from amino acid residue 31 to amino acid residue 45 of SEQ ID NO:
- 2;
- f) a sequence of amino acid residues from amino acid residue 40 to amino acid residue 45 of SEQ ID NO:
- 2;
- g) a sequence of amino acid residues from amino acid residue 40 to amino acid residue 346 of SEQ ID NO:
- 2;
- h) a sequence of amino acid residues from amino acid residue 48 to amino acid residue 346 of SEQ ID NO:
- 2;
- i) a sequence of amino acid residues from amino acid residues 29 to amino acid residue 276 of SEQ ID NO:2;
- j) a sequence of amino acid residues from amino acid residues 31 to amino acid residue 276 of SEQ ID NO:2;
- k) a sequence of amino acid residues from amino acid residues 40 to amino acid residue 276 of SEQ ID NO:2;
- l) a sequence of amino acid residues from amino acid residues 48 to amino acid residue 276 of SEQ ID NO:2;
- m) a sequence of amino acid residues from amino acid residue 278 to amino acid residue 346 of SEQ ID NO:
- 2;
- o) a sequence of amino acid residues from amino acid residue 1 to amino acid residue 346 of SEQ ID NO:
- 2;
- p) a sequence of amino acid residues from amino acid residue 29 to amino acid residue 346 of SEQ ID NO:
- 2;
- and
- q) a sequence of amino acid residues from amino acid residue 31 to amino acid residue 346 of SEQ ID NO:
- 2;
- and
- said second portion comprising another polypeptide.
An isolated polynucleotide encoding a fusion protein comprising a secretory signal sequence having the amino acid sequence of amino acid residues 1-28 or 1-30 of SEQ ID NO:2, wherein said secretory signal sequence is operably linked to an additional polypeptide.
An isolated polynucleotide comprising the sequence of nucleotide 1 to nucleotide 1084 of SEQ ID NO:13.
An oligonucleotide probe or primer comprising at least 14 contiguous nucleotides of a polynucleotide of SEQ ID NO:13 or a sequence complementary to SEQ ID NO:13.
A method for detecting a genetic abnormality in a patient, comprising:
- obtaining a genetic sample from a patient;
- incubating the genetic sample with a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1, under conditions wherein said polynucleotide will hybridize to complementary polynucleotide sequence, to produce a first reaction product;
- comparing said first reaction product to a control reaction product, wherein a difference between said first reaction product and said control reaction product is indicative of a genetic abnormality in the patient.
Dependencies are inferred from the claim text.